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ABSTRACT
Dextroamphetarnine has potential as a pharmacologic agent for the alleviation of
two common health effects associated with microgravity. As an adjuvant to space
motion sickness (SMS) medication, dextroamphetamine can enhance treatment
efficacy by reducing undesirable central nervous system (CNS) side effects of SMS
medications. Secondly, dextroamphetamine may be useful for the prevention of
symptoms of post-mission orthostatic intolerance caused by cardiovascular
deconditioning during spaceflight.
There is interest in developing an intranasal delivery form of dextroamphetamine
for use as a countermeasure in microgravity conditions. Development of this dosage
form will require an analytical detection method with sensitivity in the low ng range
(I to I00 ng/mL). During the 1995 Summer Faculty Fellowship Program, two
analytical methods were developed and evaluated for their suitability as quantitative
procedures for dextroamphetamine in studies of product stability, bioavailability
assessment, and pharmacokinetic evaluation. In developing some of the analytical
methods, fl-phenylethylamine, a primary amine structurally similar to
dextroamphetamine, was used.
The first analytical procedure to be evaluated involved hexane extraction and
subsequent fluorescamine labeling of _-phenylethylamine. Assay standard curves
were linear from 0.025 to 10/zg/mL. The lower limit of detection was 0. I ttg/mL.
When serum was spiked with drug and extracted with hexane, the standard curve was
linear in the 1.0 to I0.0 _tg/mL range. The lower limit of detection was 1.0/_g/mL.
The recovery of drug was 55 percent. The fluorescamine assay had insufficient
sensitivity for quantitation of fl-phenylethylamine at the levels which would occur in
serum or saliva. However, this method would be amenable to measuring fl-
phenylethylamine or dextroamphetamine in urine where higher drug concentrations
are observed.
The second analytical procedure to be evaluated involved quantitation of
dextroamphetamine by an enzyme-linked immunosorbent assay (ELISA). The
primary antibody was a purified, monoclonal antibody (mouse) to dextroamphetarnine.
The secondary antibody was sheep anti-mouse IgG conjugated with horse radish
peroxidase (HRP). The HRP activity was determined by measuring A490 with a
microplate reader.
For spiked human serum, the ELISA assay standard curves were linear from 50
to 1000 ng/mL. The lower limit of detection was I00 ng/mL. The sensitivity of the
ELISA procedure was comparable to the combined extraction and fluorescamine-
labeling procedures. The ELISA assay had insufficient sensitivity for quantitation of
dextroamphetamine at the levels which would occur in serum or saliva. However, if
the ELISA procedure is coupled with an organic solvent extraction procedure or with
a membrane ultrafiltration concentration procedure, the combined procedures may
prove adequate for measurement of dextroamphetamine in serum or saliva. This
possibility will be investigated in future experiments at Louisiana Tech University.
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INTRODUCTION
Dextroarnphetamine as a countermeasure
A common health effect of space flight is motion sickness which presents severe
operational decrements during early flight days (1,2). The choice treatment for this
flight specific illness is administration of promethazine intramuscularly (3).
Unfortunately, promethazine has side effects that can affect alertness and
performance. Dextroamphetamine (Dexdrine) given in conjunction with an antimotion
sickness drug such as promethazine or scopolamine has been shown to enhance the
effectiveness and reduce intensity of side effects (4). Furthermore,
dextroamphetarnine has been shown to reduce the risk and be beneficial for treatment
of vasodepressor syncope (5).
Physiologic changes of the GI function, symptoms of motion sickness, and other
related GI disturbances render oral administration of medications a undesirable option
for the effective treatment of these disturbances during space flight (6). There is
interest in examining the bioavailability and effectiveness of an intranasal dosage form
of dextroamphetamine in conjunction with promethazine. The goal is to develop
noninvasive methods of pharmacologic treatment to provide safe, effective
medications in space, as well as to offer these methods for the general benefit of
clinical populations.
During the 1995 Summer Faculty Fellowship Program, the feasibility of
developing an intranasal formulation of dextroamphetamine was examined.
Development of this dosage form will require an analytical method suitable for
conducting product stability studies, bioavailability assessment, and pharmacokinetic
evaluation. Two existing assays for dextroamphetamine analysis, fluorometric assay
and enzyme-linked immunosorbent assay (ELISA), were modified and compared.
Ultimately, the analytical methodology developed during this Summer Faculty
Program will be used to compare the bioavailability and pharmacodynamics of two
dosage forms of dextroamphetamine. Concentrations of parent drug and metabolites
will be measured in blood, saliva, and urine after intranasal (IN) and oral (IM)
administration. Pharmacokinetics and bioavailability will be estimated, and
pharmacodynamics will be assessed. The analytical methodology developed during
the Summer Faculty Program in conjunction with the ongoing research at the Johnson
Space Center may ultimately provide a new dosage form for dextroamphetamine and
may contribute to applications of the drug dextroamphetamine in space flight.
Pharmacologic background
Dextroamphetamine is a non-catecholamine, sympathomimetic amine with CNS
stimulant activity and is used chiefly for its CNS effects. D-Amphetamine exerts
most of its CNS effects by releasing biogenic amines from their storage sites in the
nerve terminals. The alerting effect of amphetamine, its anorectic effect, and at least
23-3
a componentof its locomotor-stimulating action are presumably mediated by release
of norepinephrine from central noradrenergic neurons (7).
Following an oral dose, dextroamphetamine is completely absorbed within 3
hours. It is widely distributed in the body with high concentrations in the brain.
Therapeutic blood levels range from 50 to 10 ng/mL (7). In a pharmacokinetic study
in humans, ingestion of 10 mg dextroamphetamine produced an average peak blood
level of 29.2 ng/mL at 2 hours post-administration (8). The average half-life was
10.25 hours. The average urinary recovery was 45% in 48 hours. Ingestion of a
sustained release capsule containing 15 mg produced a peak blood level at 8 to 10
hours post-administration with peak urinary recovery at 12 to 24 hours. T_he
dextroamphetamine volume of distribution was 270 liters/70 kg. The plasma protein
binding of dextroamphetamine at concentrations of 10 and 100 ng/mL was 16% bound
(9).
Urinary excretion of the unchanged drug is pH dependent (10). Urinary
acidification to pH < 5.6 yields a plasma half-life of 7 to 8 hrs. Urinary
alkalinization increases half-life ranging from 18.6 to 33.6 hours. For every one unit
increase in urinary pH, there is an average 7 hour increase in plasma half-life.
Proportionality between blood and urine data allowed an estimate of 120 mL/min for
the apparent renal clearance of amphetamine.
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METHODS
Materials
A purified monoclonal antibody against dextroamphetamine was purchased from
Biodesign International. Dextroamphetamine standard (1 mg/mL in methanol) was
purchased from Sigma Chemical Company. For fluorescamine labeling experiments,
13-phenylethylamine, a drug structurally similar to dextroamphetamine, was used as a
drug standard for assay development.
1 ml serum or standard
125 ul 4 M NaOH
8 ml hexane
vortex 30 sec
centrifuge 2500 rpm, 5 min
recover 6 ml of hexane upper phase
add 33 ul conc HCI
evporate to dryness with nitrogen
resuspend in 150 ul borate buffer (pH 9.15)
add 50 ul fluorescarnine (50 mg/dl acetone)
Record fluorescence intensity EX390/EM480
Figure 1 .- Steps in the extraction and labeling procedure for
fluorescamine assay of beta-phenylethylamine.
Extraction of/3-phenylethylamine
Aliquots of 13-phenylethylamine standard or serum spiked with/3-phenylethylamine
were prepared with a final volume of 1.0 mL in 4 inch culture tubes. Assay mixtures
received 0.125 mL of 4 N NaOH and were extracted with 8 mL hexane by vortexing
for 30 see. After centrifugation at 2,500 rpm for 5 rain, the upper organic phase was
recovered and evaporated to dryness by passing a stream of nitrogen over the sample.
The dry residue was used for fluorescamine labeling.
Fluorescamine labeling of/3-phenylethylamine
All samples to be labeled with fluorescamine were brought to a final volume of
0.15 mL with 0.1 M sodium borate buffer (pH 9.15). Each sample received 0.05 mL
of fluorescamine reagent (50 mg fluorescamine/100 mL of acetone). In preliminary
experiments, an additional 2.3 mL of 0.1 M borate buffer (pH 9.15) was added and
fluorescence intensity was measured in a 3 mL cuvette using a fluorimeter.
Excitation was at 390 nm with a bandwidth of 10 rim, and emission was measured at
480 nm with a bandwidth of 20 rim. Alternatively, the undiluted fluorescamine-
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labeledsampleswere drawn into Hoefer TKO capillary tubes, and the fluorescence
intensity was measured in a Hoefer TKO capillary cuvette.
Immunoassay of dextroamohetamine
Dextroamphetamine standards with concentrations of 0, 10, 50, 100, 500, and
1000 ng/mL were prepared in either 20 mM potassium phosphate, 150 mM NaC1, pH
7.2 (PBS) or pooled human serum. Triplicate aliquots (50 #L) of standards were
dispensed into Immulon 96-well microtiter plates and incubated over night at room
temperature. The plates were washed with five changes of Dulbecco' phosphate-
buffered saline (D-PBS) containing 1 mM magnesium chloride, 1 mM calcium
chloride, 20 mM potassium phosphate, and 150 mM NaC1 (pH 7.2) over a 20-minute
period. For 1 hr at 37°C, wells of plates were blocked with 150/_L of Blocking
Buffer containing 4% bovine serum albumin (BSA) and 4% heat-inactivated sheep
serum in calcium- and magnesium-free PBS, pH 7.2 (CMF-PBS). Blocking Buffer
was removed, and wells were washed five times with Wash Buffer containing 0.05 %
Tween 20 in D-PBS (pH 7.2). Wash Buffer was removed, and primary antibody
(mouse monoclonal anti-dextroamphetamine) was added in 50/zL of Antibody
Blocking Buffer containing 1% BSA and 1% HISS in calcium-magnesium-free PBS
(pH 7.2). Plates containing primary antibody were incubated for 2 hr at 37°C, and
wells were washed five times with Wash Buffer. Wash Buffer was removed, and
secondary antibody (horse radish peroxidase conjugated sheep anti-mouse antibody)
was added in 50/_L of Antibody Blocking Buffer. Plates containing secondary
antibody were incubated for 1 hr at 37°C, and wells were washed five times with
Wash Buffer. Wash Buffer was removed, and each well received 150/zL of
Chromagen Reaction Buffer containing 9.25 mM o-phenylenediamine, 0.2 mg%
hydrogen peroxide in 70 mM sodium citrate (pH 6.0). Reaction time was 1 hr, and
the reaction was stopped by addition of 150 _L of 2 M sulfuric acid. Absorbance
was measured at 490 nm with a plate reader.
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RESULTS AND DISCUSSION
Calibration of spectrofluorimeter with riboflavin
To calibrate the spectrofluorimeter for use in fluorescence measurements, a
riboflavin standard curve was prepared, and native fluorescence was measured.
Concentrations of standards ranged from 0.4 to 40 ng/mL. Samples volumes were
2.5 mL, and fluorescence intensity was determined in a 3 mL cuvette with 1 cm light
path. By performing excitation and emission scans, the optimum wavelengths for
detection of native fluorescence were excitation at 425 nm and emission at 530 nm.
The standard curve was linear from 0.4 to 30 ng/mL (data not shown).
Labeling of/3-phenvlethylamine with fluorescamine
Ten B-phenylethylamine standards with 0.15 mL volume in 0.1 M borate buffer
(pH 9.15) were prepared. The standard concentrations ranged from 0.01 #g to 100
#g per tube. A 0.05 mL solution of fluorescamine reagent was added to each tube.
The mixtures were further diluted with 2.3 mL of borate buffer, and fluorescence
intensity was measured in a 3 mL cuvette with 1 cm light path. By performing
excitation and emission scans, the optimum wavelengths for detection of
fluorescamine-labeled B-phenylethylamine were excitation at 390 nm with a bandwidth
of 10 nm and emission at 480 nm with a band width of 20 nm. The standard curve
was linear from 0.05 to 10 #g per tube (data not shown).
Percent recovery of _-phenvlethylamine from serum
Water or serum was spiked with 0, 1, 5, or 10/zg of _-phenylethylamine. The
samples were extracted and labeled with fluorescamine. The fluorescence intensity
was determined using a 3 mL cuvette. A set of standards which was not extracted
was also assayed so that recovery could be estimated (Fig. 2). The recovery of fl-
phenylethylamine from water was 80%, while the recovery from serum was 55%.
Requirement of acid addition before evaporation to dryness
The fluorescamine labeling reaction is strongly pH dependent with a pH
maximum of 8.0 to 9.5. The extraction procedure includes the addition of 33/xl of
concentrated HC1 to the hexane aliquot before evaporation to dryness. To determine
if the addition of HC1 to the hexane extract before evaporation was essential to the
labeling reaction, water and serum standards of fl-phenylethylamine were prepared
and extracted. The organic phase was evaporated to dryness either with or without
the 33/_1 concentrated HCI addition. After labeling, fluorescence intensity was
determined using a 3 mL cuvette. When acid was added before evaporation, the
recovery of fl-phenylethylamine was 80% from water and 55% from serum (Fig. 3).
When acid addition was omitted, recoveries from water and serum were 20% and
15%, respectively (Fig. 3). Addition of concentrated HCI was required for successful
labeling of B-phenylethylamine.
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In another experiment, the amount of concentrated HCI added to the hexane
extract before evaporation was doubled to 66 #1. The percent recovery for both water
and serum samples was unchanged by doubling the HC1 addition (data not shown).
The results suggest that HC1 addition is required and that 33 to 66 #1 of concentrated
HC1 is an adequate addition to support subsequent fluorescamine labeling.
Effect of mechanical mixing on drug extraction
The effect of prolonged mechanical mixing on drug recovery was examined.
Spiked water and serum samples were extracted by either 30 rain rotation on a clinical
mixing table or by 30 sec vortexing by hand. The percent recovery for both water
and serum samples was unchanged by 30 min agitation versus simple vortexing. This
demonstrates that the more elaborate extraction procedure is not required (Data not
shown).
Use of capillary_ cuvette to measure fluorescence intensi _ty
The use of a 3 mL quartz cuvette for measuring fluorescence intensity
necessitated the dilution of the 0.2 mL labeling mixture to 2.5 mL. To avoid this
dilution, a Hoefer TKO capillary cuvette and TKO quartz capillary tubes were
employed to measure the fluorescence intensity of undiluted 0.2 mL samples after
labeling. For a 10 _g/mL standard, the fluorescence intensity for the diluted 2.5 mL
samples and undiluted 0.2 mL samples were 21 and 98, respectively (Fig. 4). For all
subsequent assays, the capillary cuvette was employed, and dilution of labeled
samples was avoided.
To further examine the utility of the capillary cuvette, serum samples were spiked
with/3-pheynylethylamine to create a standard curve ranging from 0.01 to 1 _tg/mL.
Samples were extracted with hexane. After labeling with fluorescamine, the
fluorescence intensity was determined using the capillary cuvette. A standard curve
of/3-phenylethylamine in water was also prepared and labeled without extraction.
The standard curve for unextracted samples was linear from 0.025 to 1/zg. The
lower limit of detection was 0.025 to 0.1 #g (Fig. 5). Although unextracted aqueous
samples could readily be assayed in the 0.1 to 1 #g range, recoveries for extracted
serum samples were low, and quantitation was not possible from serum. The
fluorescence intensity of extracted serum samples was only slightly higher than
blanks. The capillary cuvette method increased the fluorescence intensity of samples,
but the sensitivity of the method was not improved by this technique.
Time dependence of fluorescamine labeling
The labeling of primary amines with fluorescamine is both pH and time
dependent. Several 10 #g samples of/3-phenylethylamine were prepared and labeled
for different times ranging from 5 to 30 min. The extent of labeling was unchanged
throughout the time interval examined and did not increase for incubations as long as
either 2 or 3 hr (data not shown).
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Figure 6.- ELISA standard curve of dextroamphetamine in human serum.
Enzyme-linked immunosorbent assay of dextroamphetamine
Enzyme-linked immunsorbent assays (ELISA) have been used to measure ng and
pg quantifies of proteins, peptides, and drugs in biological specimens. A purified,
monoclonal antibody to dextroamphetamine was purchased and used to measure
dextroamphetamine in spiked human serum. As shown in Fig. 6, a linear standard
curve was obtained in the range of 50 to 1000 ng/mL. The lower limit for
dextroarnphetamine detection in spiked human serum was 100 ng/mL.
The lower limit for detection of dextroamphetamine by ELISA was similar to the
lower limit for dextroamphetamine detection by the fluorescamine labeling procedure.
However, the ELISA procedure involved the detection of dextroamphetamine in only
50/zl of serum, whereas the fluorescamine procedure involved extraction and assay of
dextroamphetamine from 1 mL of serum.
It is anticipated that much lower limits of detection could be obtained by the
ELISA procedure if serum dextroamphetamine samples could be concentrated before
analysis. Concentration of serum dextroamphetamine samples could be accomplished
by either extraction with organic solvents or by membrane ultrafiltration coupled with
Speed-Vat solvent evaporation. Studies of the utility of these concentration
procedures for enhancing ELISA measurement of dextroamphetamine will be
continued in the Biochemistry Program at Louisiana Tech University.
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CONCLUSIONS
Primary amines such as 13-phenylethylamine were readily extracted from
alkalinized serum by hexane. Recoveries ranged from as high as 80 % for aqueous
solutions of the amine to about 50 % for spiked serum samples.
Hexane extraction of i3-phenylethylamine followed by covalent labeling of the
primary amine with fluorescamine was a viable analytical procedure for quantitation.
Assay standard curves were linear from 0.025 to 10 #g/mL. The lower limit of
detection was 0.1 ttg/mL for aqueous solutions of the amine and 1.0 gg/mL for
spiked serum.
The fluorescamine assay had insufficient sensitivity for quantitation of B-
phenylethylamine at the levels which would occur in serum or saliva. However, this
method would be amenable to measuring B-phenylethylamine or dextroamphetamine
in urine where higher drug concentrations are observed.
The enzyme-linked immunosorbent assay (ELISA) procedure proved to be a
viable analytical method for determination of dextroamphetamine. The primary
antibody was a purified, monoclonal antibody (mouse) to dextroamphetamine, and the
secondary antibody was sheep anti-mouse IgG conjugated with horse radish
peroxidase (HRP). For spiked human serum, the ELISA assay standard curves were
linear from 50 to 1000 ng/mL. The lower limit of detection was 100 ng/mL.
The sensitivity of the ELISA procedure was comparable to the sensitivity of the
combined hexane extraction/fluorescamine-labeling procedures. The ELISA assay had
insufficient sensitivity for quantitation of dextroamphetamine at the levels which
would occur in sentm or saliva. However, if the ELISA procedure is coupled with an
organic solvent extraction procedure or with a membrane ultrafiltration concentration
procedure, the combined procedures may prove adequate for measurement of
dextroamphetamine in serum or saliva. This possibility will be investigated in future
future experiments at Louisiana Tech University.
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